img

Mastering Execution & Risk in Integrated Drug–Device Clinical Trials

Course Description

Integrated drug–device clinical trials introduce a level of operational complexity that extends beyond traditional clinical trial models. Misalignment between drug, device, and software components can lead to delays, data integrity risks, and regulatory challenges.

This 2-day virtual training course provides a practical, execution-focused framework for designing, managing, and overseeing integrated trials, with emphasis on risk identification, cross-functional coordination, monitoring strategy, and inspection readiness. Skills are reinforced through a combination of activities, including case-based learning, interactive exercises, and scenario simulations.

Course at a Glance

2-Day Live Virtual Workshop
2 Full Days of Interactive Learning

Intensive, instructor-led sessions

June 13-14,2026

Upcoming Virtual Workhop

9:00 AM - 4:00 PM EST

Small-group, live instructor-led sessions

Price : $1995.00 USD
location Created with Sketch Beta.
Location:

Participate from anywhere with stable internet

certificate-ribbon-solid
Certificate of Completion from CRTA

Recognized professional credential

Faculty Director: Sonja Cooper
Limited Seats - Secure Your Spot Early!

Learning Objectives

By the end of this course, participants will be able to:

  • Identify key operational risks unique to integrated drug–device trials
  • Align regulatory strategy with clinical operations execution
  • Design protocols that are operationally feasible and scalable
  • Implement risk-based monitoring strategies tailored to integrated trials
  • Apply RBQM principles using KRIs, QTLs, and centralized monitoring
  • Strengthen site performance and recruitment strategies
  • Prepare for regulatory inspections with confidence
  • Build sustainable, repeatable operational models across trials

Who Should Attend

  • Clinical Operations Leaders (Manager–Director level)
  • RBQM / Central Monitoring Leaders
  • Clinical Study Leads / Program Managers
  • Data Management & Biostatistics Professionals
  • Regulatory Affairs & Quality Professionals
  • Device / Digital Health Clinical Teams

Course Outline

Day 1 – Understanding Complexity & Failure Points

Session 1: Why Integrated Trials Break

  • Key differences vs traditional trials
  • Early-stage failure points
  • Hidden cross-functional dependencies

Session 2: Regulatory Strategy & Operational Impact

  • FDA and Health Canada frameworks
  • IND, IDE, CTA, ITA implications
  • How regulatory decisions impact timelines and execution

Session 3: Protocol Design for Execution

  • Drug + device + software alignment
  • Human factors and usability considerations
  • Version control and amendment management
  • Endpoint complexity

Session 4: Feasibility & Site Strategy

  • Site capability vs experience
  • Training and device readiness
  • Recruitment challenges (including rare disease considerations)
  • Site burden and feasibility risks
Day 2 – Execution, Monitoring, Quality, and Inspection Readiness

Session 5: Cross-Functional Execution

  • Aligning Clinical Ops, Engineering, Regulatory, QA
  • Vendor ecosystem management
  • Communication strategies

Session 6: Monitoring & Oversight

  • Device accountability and traceability
  • Training verification
  • Software-related deviations
  • Risk-based monitoring strategies

Session 7: RBQM & Centralized Monitoring

  • KRIs, QTLs, and signal detection
  • Data sources beyond EDC
  • Integrated risk-based monitoring models

Session 8: Quality & Risk Management

  • CAPA and change management
  • Documentation challenges
  • Risk lifecycle management

Session 9: Inspection Readiness

  • Common regulatory findings
  • Red flags during inspection
  • Bridging gaps between operations and regulatory expectations

Session 10: Sustainable Operating Models

  • Standardization across trials
  • Process scalability
  • Continuous improvement of frameworks
Interactive Components
  • “What Breaks First?” Risk Identification Exercise

  • Protocol Risk Assessment Workshop

  • Cross-Functional Conflict Simulation

  • “Fix the Broken Trial” Capstone Case Study

Course Deliverables

Participants will receive:

  • Integrated Trial Risk Assessment Framework
  • Monitoring Strategy Template (Drug + Device)
  • Site Capability Assessment Tool
  • RBQM Implementation Guide
  • Inspection Readiness Checklist
Evaluation & Completion
  • Knowledge check (interactive quiz)
  • Participation in exercises and discussions
  • Capstone scenario performance
Key Takeaways

Participants will leave with:

  • A clear operational framework for integrated trials
  • Practical tools for immediate application
  • Enhanced ability to identify and mitigate risks early
  • Strategies to improve monitoring quality and site performance
  • Confidence in supporting inspection readiness and regulatory success
Sonja Cooper,
Faculty Director’s Bio:

Sonja Cooper,

BS, PhD, MBA

Dr. Sonja Cooper is a clinical operations and risk-based quality management leader with over 20 years of experience driving global clinical trial execution across complex, multi-regional programs. She specializes in building high-performing clinical monitoring and operational frameworks that ensure data integrity, regulatory compliance, and accelerated study delivery.

Dr. Cooper has led cross-functional teams spanning clinical operations, central monitoring, and trial master file (TMF) oversight, consistently improving study timelines by up to 25% while maintaining a 95% compliance rate. She is recognized for implementing data-driven strategies, including RBQM frameworks, centralized monitoring, and operational analytics, to proactively identify risk and enhance trial performance.

Her expertise spans oncology, rare disease, and complex therapeutic areas, with a strong track record of optimizing site performance, improving patient recruitment, and strengthening sponsor and CRO partnerships. She has also contributed to business development efforts, securing over $15 million in clinical trial revenue through strategic collaboration and operational excellence.

Dr. Cooper holds a PhD in Organizational Leadership, an MBA, and a Bachelor of Science in Biology and Chemistry. She also holds a graduate certificate in AI in Healthcare from Harvard University, reflecting her commitment to advancing data-driven clinical innovation.

Become Our Faculty Director Today

Be part of a global network of virtual and in-person workshops

Global Pharma companies and CROs employing our graduates

Global Pharma companies and CROs
employing our graduates